Bipolar Disorder
📧 Sign up to get email alerts when something new happens for Bipolar Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-03-22Clinical Trial Update: Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder [Phase 3]
Phase 3 study evaluating licarbazepine for manic episodes in bipolar disorder has completed.
-
CLINICAL_TRIALS trial_result · 2017-03-22Clinical Trial Update: Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder [Phase 3]
A Phase 3 trial investigating licarbazepine for manic episodes in bipolar disorder has completed enrollment and status is reported as comple…
-
CLINICAL_TRIALS trial_result · 2017-03-17Clinical Trial Update: Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes [Phase 3]
Phase 3 trial assessing switching between different strength forms of FK949E in bipolar depression; results were posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-03-16Clinical Trial Update: Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating intranasal ketamine for pediatric bipolar disorder has been terminated.
-
CLINICAL_TRIALS research · 2017-03-13Clinical Trial Update: The Immune System and Psychiatric Disorders
The update summarizes a completed clinical trial investigating potential links between the immune system and several psychiatric disorders, …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-03-09Clinical Trial Update: Integration of Illness Management and Recovery Within ACT [NA]
A completed clinical trial update describes integrating Illness Management and Recovery within Assertive Community Treatment for individuals…
-
FDA approval · 2017-03-06FDA Approved: DEPAKOTE SPRINKLES — Supplemental Application (AbbVie Inc.)
FDA approves a supplemental application for Depakote Sprinkles (divalproex sodium) from AbbVie, authorizing changes to the product labeling …
-
FDA approval · 2017-02-23FDA Approved: ZYPREXA INTRAMUSCULAR — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for ZYPREXA INTRAMUSCULAR (olanzapine) from Eli Lilly and Company, adding the intramuscular formulat…
-
FDA approval · 2017-02-23FDA Approved: ZYPREXA ZYDIS — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for ZYPREXA ZYDIS (olanzapine) from Eli Lilly and Company.
-
FDA approval · 2017-02-23FDA Approved: RISPERIDONE — Supplemental Application (Janssen Pharmaceutical, Inc.)
FDA approved a supplemental application for Risperidone submitted by Janssen Pharmaceutical, Inc. The action pertains to an addition or modi…
-
FDA label_change · 2017-02-23FDA Approved: RISPERDAL — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Risperdal (risperidone) from Janssen Pharmaceuticals, resulting in changes to the product la…
-
FDA approval · 2017-02-23FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Geodon (ziprasidone) submitted by Viatris Specialty LLC. This action relates to an approved supp…
-
FDA approval · 2017-02-23FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Geodon (ziprasidone) submitted by Viatris Specialty LLC.
-
FDA approval · 2017-02-23FDA Approved: SEROQUEL XR — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for SEROQUEL XR (quetiapine) from AstraZeneca Pharmaceuticals LP, updating or expanding its labeling…
-
FDA approval · 2017-02-23FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for chlorpromazine hydrochloride (Upsher-Smith Laboratories), updating an existing product's lab…
-
FDA approval · 2017-02-23FDA Approved: HALOPERIDOL — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application for HALOPERIDOL from Lannett Company, Inc., under an Abbreviated New Drug Application (ANDA). Th…
-
FDA approval · 2017-02-23FDA Approved: VRAYLAR — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for VRAYLAR (cariprazine) submitted by Allergan, Inc.
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Simvastatin Augmentation of Lithium Treatment in Bipolar Depression [Phase 2]
This Phase 2 clinical trial update reports results for simvastatin augmentation of lithium in bipolar depression; the study (NCT01665950) wa…
-
FDA approval · 2017-02-23FDA Approved: CHLORPROMAZINE HCI — Supplemental Application (Dr. Reddy's Laboratories Inc.,)
FDA approved a supplemental application for Chlorpromazine HCl by Dr. Reddy's Laboratories Inc., granting approval for a generic version of …
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Spot Depression Study
The update notes the completion of the Spot Depression Study (NCT02804867) conducted by the University of Cambridge, investigating treatment…
-
FDA approval · 2017-02-23FDA Approved: ARIPIPRAZOLE — Supplemental Application (Apotex Corp.)
FDA approved Apotex Corp.'s supplemental application for aripiprazole, enabling the generic version to be marketed.
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder [Phase 3]
Phase 3 clinical trial update evaluating licarbazepine for manic episodes in bipolar disorder. The study status is completed.
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder. [Phase 3]
An open-label extension study assessing the safety and tolerability of licarbazepine for manic episodes in Bipolar I Disorder. The update su…
-
FDA approval · 2017-02-23FDA Approved: ARIPIPRAZOLE — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application to authorize a generic aripiprazole product by Lannett Company, Inc. under ANDA204171.
-
CLINICAL_TRIALS withdrawal · 2017-02-17Clinical Trial Update: Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy [NA]
This clinical trial update reports the withdrawal of a Kaiser Permanente study evaluating ultrabrief right unilateral and brief-pulse electr…